Monday, November 13, 2017

Share Investor Admin

You can now get me and my scribbles at the following URL's

You can now get my blog and forum at the following URLS - A range of financial type websites from Share Investor Share Investor Forum - Share Investor Forum - Share Investor Forum - Share Investor Forum - Share Investor Blog - Share Investor Blog 

c Share Investor 2017

Thursday, November 9, 2017

Xero: Interview with Rod Drury Coming - Reader Questions Submitted

Image result for rod drury

Ive secured an Interview with Rod Drury, from Xero Ltd. It will be in the form of questions put to Rod about his company via email. 

Where to from here and why. 

What I want from you dear reader is questions. Relevant ones, please. 

Put your questions down here and I will submit them.

Either email questions @ or leave the at the bottom of this post.



*Addendum  I have to add. If I don't get enough questions over 2 weeks, the Interview will not go ahead.

Share Investor Q  As

Convention Centre proposal interview with Sky City CEO Nigel Morrison

c Share Investor 2017

Wednesday, November 1, 2017

Share Investor; Guest Post: Study suggests link between A1 beta-casein and type 1 diabetes

Share Investor note:

This article was published yesterday after much too ing and fro ing.

It was included here at Share Investor for one reason.

I believe it gives weight behind the argument that A1 vs A2 milk and I will leave it up to the reader to decide which way they believe.

Its inclusion on this blog is to do with the financial possibilities this sort of "research" has.

I'm not a big milk drinker of either A1 or A2 milk.

I'm neither a holder in any stock to do with this story.

[The article below was intended to be published some weeks back at The Conversation. The Conversation is the online portal, funded by Universities in Australia, New Zealand and the UK, where academics are encouraged to communicate and converse with non-academics. However, this particular article was blocked at the last minute by the Senior Editor(s) at The Conversation, having previously been approved within their editorial system. The Senior Editor(s) felt that the interests of associated commercial parties, who might benefit from dissemination of the article, were too great. A fuller story of that publishing saga will be posted shortly.

The content, formatting and supporting links are shown as originally agreed with The Conversation and reflect the prior input of one of their editors. This article can be freely republished, with acknowledgements as to source [].
Authors: Keith Woodford & Boyd Swinburn
Disclosures: See end of article
Type 1 diabetes, an autoimmune disease in which the body attacks its own insulin-producing cells, is on the rise globally.

Early evidence of an association between type 1 diabetes and a protein in cow milk, known as A1 beta-casein, was published in 2003. However, the notion that the statistically strong association could be causal has remained controversial.

As part of a seven-person team, we have reviewed the overall evidence that links A1 beta-casein to type 1 diabetes. Our research brings forward new ways of looking at that evidence.
Different types of diabetes

Type 1 diabetes is the form of diabetes that often manifests during childhood. The key change is an inability of the pancreas to produce insulin, which is essential for transporting glucose across internal cell membranes.

There is common confusion between type 1 and the much more common type 2 diabetes. Type 1 diabetes is an autoimmune disease. This means that the immune system attacks the body’s own cells. Insulin-producing cells in the pancreas are then destroyed by “friendly fire”.

There is no accepted lifestyle change that will prevent or cure type 1 diabetes and daily insulin injections are required throughout life.

In contrast, people who develop type 2 diabetes still produce some insulin, but the liver and muscles become resistant to insulin’s ability to move glucose out of the blood and into the tissues. Type 2 diabetes is primarily a disease of middle-aged and older people and is related to excess weight, diet and lack of physical activity.
A1 beta-casein comes from European-type cows

If A1 beta-casein is indeed triggering type 1 diabetes, then this would be of profound importance. Globally, there are approximately 78,000 new cases diagnosed in young people every year, with many additional cases diagnosed in adults.

Cows of European origin are the only source of A1 beta-casein. It is the result of a mutation, probably some thousands of years ago. Some of these cows produce beta-casein that is all A1, others produce a mix of A1 and another type known as A2, and others produce only the A2 type.

Goats, sheep, Asian cattle, buffalo, camels and indeed humans produce milk only of the A2 type.

A1 beta-casein, on digestion, releases a peptide (protein fragment) which has opioid and inflammatory characteristics. The protein fragment is called beta-casomorphin-7 (“caso” from casein, “morphin” from morphine-like, and 7 to indicate the fragment contains seven amino acids).

The release of this protein fragment is accepted science; it is the implications that have been controversial. There is scientific literature that links A1 beta-casein to multiple health conditions, but here, we restrict ourselves to type 1 diabetes.
Evidence but no definitive proof

The evidence in our paper comes from 71 studies covering population epidemiology, animal trials, in vitro laboratory experiments, biochemistry and pharmacology. Our assessment is that the evidence is highly suggestive that A1 beta-casein is associated with the onset of type 1 diabetes, but proof remains elusive. There have been no clinical trials specifically investigating a long-term diet free of A1 beta-casein.

Such trials would be very expensive and difficult, but not impossible, to conduct. People who are genetically susceptible to developing type 1 diabetes would need to be identified at birth and half of them randomly allocated to a diet free of A1 beta-casein for many years.

Clinical trials are very powerful when the effects are quickly evident. However, they are seldom practical when outcomes are caused by prolonged exposure to a particular food or other environmental factor, and where effects may take many years to manifest.

In these situations, other methods based on epidemiology, often combined with insights about biological mechanisms, provide the underpinnings for public health actions.
Type 1 diabetes varies between countries

Studies across countries show very high correlations between type 1 diabetes incidence (with a variation of 280-fold) and intake of A1 beta-casein (more than five-fold variation).
Figure 1: Correlation between A1 β-casein supply per capita in 1990 and type 1 diabetes incidence (1990–1994) in children aged 0–14 years in 19 countries. Original source here
Such country-level studies are sometimes criticised because statistical associations between populations do not necessarily apply at the individual level. However, the A1 beta-casein results are very stable in that they are not dependent on one or two outlier countries and no-one has come up with an alternative explanation as to what could explain such very high correlations.

In our paper, we report recent evidence from China where type 1 diabetes was almost unknown in the past. Now, it is increasing rapidly along the developed eastern seaboard. There is published data for two cities.

In Shanghai, the incidence (new cases) increased at 14.2% compound rate each year between 1997 and 2011. In Zhejiang (a major city south of Shanghai) it increased at 12% percent compound rate per annum between 2007 and 2013. These increases are mirrored by China’s increased per capita dairy consumption from 6kg in 1992 to 18kg in 2006, and with further substantial increases thereafter. There are no other apparent explanations for this rapid rise in Type 1 diabetes in China.
Bovine milk has previously been identified as a potential risk factor for Type 1 diabetes. There have been multiple trials comparing breast milk to formula, and also comparing alternative ages of first introduction to bovine milk. But clear answers have been elusive.
Those inconsistent results are not surprising if the problem is indeed A1 beta-casein, which has such variability of levels between countries. None of these trials have specifically compared A1 beta-casein to A2 beta-casein, and none of the trial treatments have been long term post-weaning. In essence, these trials have lacked the necessary specificity.
Predisposing factors

While A1 beta-casein may be the primary causal agent, there are probably many predisposing factors. A genetic predisposition has been known for some time but other factors such as infections and antibiotics which affect the intestinal mucosal barrier may prime the immune system to turn against the body. Inadequate Vitamin D levels may also be predisposing in some situations, although the evidence for this is limited.
Figure 2: Proposed Type 1 diabetes mechanisms (Source: here )
It is clear that none of the multiple predisposing factors are capable of being causal by themselves; instead they create the environment where a trigger can do its damage. Accordingly, the key is to remove either the trigger or all the predisposing factors. When predisposing factors are multiple, it is usually easiest to remove the key trigger.
Public health and personal choice

It is feasible to breed all dairy herds to produce milk free of A1 beta-casein. The catch is that it would take at least ten years in most countries, even if all dairy farmers used only A2 bulls and A2 semen in breeding programmes from now on.

However, cow milk free of A1 beta-casein is increasingly available in many Western countries, including New Zealand, Australia, the USA and Britain. Goat and sheep milks are other options for those seeking milk that is free of A1 beta-casein.

In the absence of definitive proof, consumers have to make their own choices. This is particularly important in situations where there is a family history of type 1 diabetes. However, the increasing incidence means that type 1 diabetes is increasingly showing up in families without that prior family history, and this is particularly relevant to parents of infants and young children.

An open access version of the research is available here.

Boyd Swinburn is Professor of Population Nutrition and Global Health at Auckland University. He was commissioned in 2004 by the New Zealand Food Safety Authority to review the health evidence at that time relating A1 and A2 beta-casein. That report is available at
He has no other disclosures relevant to beta-casein issues.

Keith Woodford holds an honorary position as Professor of Agri-Food Systems at Lincoln University (i.e., retired but still active academically). He consults for but remains independent of a range of agri-food companies, some of whom have interests in issues of beta-casein. He authored the book ‘Devil in the Milk’, published in 2007 in New Zealand (Craig Potton Publishing, now Potton and Burton), with an American version published in 2009 (Chelsea Green), and an updated NZ/Australian version in 2010 (Potton and Burton). He writes regularly on beta-casein issues at . He has co-authored five peer-reviewed papers in international science and nutrition journals on beta-casein issues. He has no shareholding in any dairy company.

Tuesday, October 31, 2017


Image result for asb securities

Mmm, now it appears I don't get the live data from unless I buy shares now.

I have it in front of me now only because of a purchase I made yesterday.

My question is do you get this data free or do you have to pay?

It almost is the last straw for me on top of numerous outs of ASB's website.

This really seems unfair because I purchase currently around 6 times a year and I recall some 2 weeks ago that they would be moving to this new system because of the horrendous cost of the data but they gave me no choice as to what it was I wanted to do.

I might have wanted to buy the data when they switched over a few days ago.

Now they have me sniffing around at other opportunities and writing stuff like this.

Do you have some suggestions?

More Banking Madness @ Shareinvestor

Westpac: I'm Thinking of Returning

Monday, October 30, 2017

Share Investor has a second go at Tourism Holdings

Just managed to get hold of 3000 Tourism Holdings Ltd [THL.NZX] for $5.03.

That is all I've managed to scrape together given my obvious financial straits.

It seems the Chinese company HB Holdings has so far gained an almost 11 per cent stake.

I think I last owned this back in 2004 - 2005? and from memory it was 1000 shares.

I think I bought it for $4 something and sold it for $2 something.

I hope to sell it to the Chinese for $7 plus.

Really when you are looking at Chinese and control, no price is really relevant.

We soon will see what it is the price will be.

A possible partnership stake up to the required 19 or 20 per cent is possible but methinks the Chinese will want to get in on the action before Winston Peters and his hatred for Chinese comes into force in the form of stopping this thing from happening - a takeover.

Stay tuned.

Tourism Holdings @ Share Investor

Share Price Alert: Tourism Holdings Ltd
Tourism Holdings worth more broken up
Long Term View: Tourism Holdings Ltd
2011 World Cup Fever

Discuss THL @ Share Investor Forum

c Share Investor 2017

Wednesday, October 18, 2017

TIN's top 10 technology companies by revenue growth in year June 17

Technology Investment Network managing director Greg Shanahan says it has been a defining year for New Zealand's highest ...

Technology Investment Network link to story @ Stuff 
The top 10 "Tech" companies 3 of them listed and one on the way to the top - Fisher & Paykel Healthcare.
It would be nice to see couple of these listed. Datacom & Gallagher would be two Id be interested in.

TIN's top 10 technology companies by revenue growth in year June 17

1. Datacom Group - $1.15b
2. Fisher & Paykel Appliances - $1.14b
3. Fisher & Paykel Healthcare - $894m 
4. Xero​ - $295m
5. Gallagher - $232m
6. Orion Health - $199m
7. Douglas Pharmaceuticals - $189m
8. Tait Communications - $175.2m (estimated) 
9=. NDA Group - $175m
9=. Temperzone Group - $175m
10. Magic Memories - $154m

Tuesday, October 17, 2017

Share Market Not Like it Was 30 Years Ago

Image result for 1987 stock market crash newspapers in new zealand herald
Looked for photo in the Herald but could only find this one. Picture tells a thousand words.

Share Investors Portfolio @ 17 Oct 2017

The question raised by most pundits this week is will the 1987 share market crash that happened in this country on the 20th October 1987 and in the rest of the world the day before happen again?

I would contend its not when it will happen because it will.

I don't pretend to know just when it will because I don't know.

Lets be clear, the reasons for the 87 crash were varied and wide - depending on who you talk to - but the reasons in this part of the world were a lot different to those in the Northern Hemisphere.

Here apart from anywhere in the world we were going through a vast transformation. 

Business was moving and becoming clearer and cleaner. Restrictions to all business were removed and we were at the centre of a global experiment which was being watched from Wall Street to Fleet St and then tried there in the 1990's and 2000's. 

NZ INC was closed one minute - under Rob Muldoon and then open the next day thanks to Roger Douglas.

Capital moved in from overseas then we were in the grip of a financial tsunami, the likes of which we hadn't seen before.

And what did people invest in?

Bugger all really.

Most of the businesses floated on the stock market at that time had very little to do with real business and those that were doing "good" business were taken along for the ride.

Unfortunately these good businesses were taken down on the 20th October 1987 along with the other ones that shouldn't have been listed in the first place.

Fast forward to today when we have restrictions and various rules around investing on the NZX - there are certainly not enough but its getting there.

The share market is a vastly different space to what it was 30 years ago.

We have companies that actually make money and for the ones that don't have yet it is in investors hands whether they stay or go. 

It is largely up to the investor how much risk they are will to take or make.

BUT and it is a healthy but. There has been risk as long as there has been 2 people willing to trade with each other.

Inherently there is greed and that is the key word and there is no way you will ever get around it.

As long as we have greed and avarice we can be assured that we will have another share market crash.

Just when?

Share Investors Portfolio @ 17 Oct 2017

Share Investor Reading

New Zealand Stockmarket: A History from beginning to present day. 
Stockmarket Education: How do you buy shares? 
Stockmarket Education: What is a Share? 

Stockmarket Education 

Stockmarket Dictionary 
Stockbrokers: What you should know before choosing one 
10 Basic questions to ask before investing 
How the Stockmarket works 
Understanding Risk 
Watch Your Risk Tolerance 
Stockmarket Education: What is a Share? 
What Moves the Stockmarket? 
7 Signs of Shareholder Friendly Management 
Financial Media For Investors 
Dividends in detail 

Related Links

NZX - How to Invest 

c Share Investor 2017

Wednesday, October 11, 2017

Fisher & Paykel: The Biggest Listed Company in New Zealand

Growing demand for Fisher & Paykel Healthcare's products have been keeping its Auckland manufacturing plant busy.
Technology has overtaken tourism at the top of the NZX, with exporter Fisher & Paykel Healthcare ousting Auckland Airport as the country's most valuable company.

Note from Share Investor: Was taken on a ride with this one over the last 5 years and I don't think its finished yet.
In one way or another its fate will be determined over the next few years not so much by Fisher and Paykel [FPH.NZ] but they will continue how they have done business since year one, that is without fear or favour of anything political. They will just get on with business regardless but politically the share FPH is definitely in favour.
Watch for a big rise in share price if Winston Peters goes with either left, left, left of centre Labour or left of centre party National tomorrow or Friday or whenever he feels like it. 
Look for the dollar to reach lows next year if Winnie the Pooh gets his way and the dollar is somehow uncoupled from the mood of the economy. As it has been for many decades now then the sky is just about the limit for this share. 
I could be proven wrong but something tells me 3 million dollars for every movement per cent in the dollar is the figure.
F & P have forward cover for this but as soon as this is used all bets are off.

F&P Healthcare shares have been on a five-year bull run as the company has expanded its hospital and home sales of medical devices that treat breathing disorders.
The company is now worth $7.446 billion – a few hundred thousand dollars more than Auckland Airport which was relegated into second place on the NZX at the close of trading on Wednesday.
F&P Healthcare shares have been boosted in recent weeks by a decline in the value of the New Zealand dollar, which has the effect of boosting its export revenues and profit margins.
A decline in the Kiwi that followed confirmation of the election result on Saturday has helped provide the impetus to take F&P Healthcare over the line.
Shares in the company closed 17 cents higher at a record high of $13.05 on Wednesday, while Auckland Airport shares had slipped 2c to $6.24 just before 5pm.
F&P Healthcare shares had a small wobble last year.
One cause was concerns over the President Trump's threats to renegotiate a trade agreement with Mexico – where F&P Healthcare has its American manufacturing base.
Another was concern over tit-for-tat patent litigation by Californian Resmed.
Resmed said the New Zealand firm's masks, designed to treat sleep apnoea, violated its patented technology after F&P Healthcare launched its own litigation.
Nerves about the litigation may have been calmed after a German court suspended Resmed's two patent proceedings pending the outcome of a European Patent Office decision over the patents. 

Fisher & Paykel Healthcare @ Share Investor

Share Investor Portfolio @ Oct 11 2017

Fisher & Paykel Healthcare Ltd: Where is it Going?
Fisher & Paykel Healthcare Ltd:  Should I Buy Now?
Fisher & Paykel Healthcare Ltd: The Time to Buy
Share Investor's 2012 Stock Picks
Global Market Sell-Off Stocks: Fisher & Paykel Healthcare
Resmed takes market share from Fisher & Paykel Healthcare
Resmed kicking Fisher & Paykel Heathcares butt?
Share Price Alert: Fisher & Paykel Healthcare Ltd
I'm Buying: Fisher & Paykel Healthcare Ltd
Share Investor's Total Returns: Fisher & Paykel Healthcare Ltd
Share Investor's 2011 Stock Picks
Stock of the Week: Fisher & Paykel Healthcare Ltd
Fisher & Paykel Healthcare & the US Dollar
Mondrian Investment Partners take stake in Fisher & Paykel Healthcare
Fisher & Paykel Healthcare: 2010 Full Year Profit rests on Foreign exchange movement
Long Term View: Fisher & Paykel Healthcare
Stock of the Week: Fisher & Paykel Healthcare
Analysis - Fisher & Paykel Healthcare: FY Profit to 31/03/09
Schroder Investment Management takes big Fisher & Paykel Healthcare stake
Long VS Short: Fisher & Paykel Healthcare
Big Fisher & Paykel Healthcare trades a curious tale

Why did you buy that stock? [Fisher & Paykel Healthcare]
Drinking and Trading
Share Investor's 2008 stock picks
Fisher & Paykel: A tale of two companies
FPH downgrade masks good performance

Discuss FPH @ Share Investor Forum
Download FPH Company Reports

Share Investor 2017